Multimodal fusion of liquid biopsy and CT enhances differential diagnosis of early-stage lung adenocarcinoma
© 2024. The Author(s)..
This research explores the potential of multimodal fusion for the differential diagnosis of early-stage lung adenocarcinoma (LUAD) (tumor sizes < 2 cm). It combines liquid biopsy biomarkers, specifically extracellular vesicle long RNA (evlRNA) and the computed tomography (CT) attributes. The fusion model achieves an impressive area under receiver operating characteristic curve (AUC) of 91.9% for the four-classification of adenocarcinoma, along with a benign-malignant AUC of 94.8% (sensitivity: 89.1%, specificity: 94.3%). These outcomes outperform the diagnostic capabilities of the single-modal models and human experts. A comprehensive SHapley Additive exPlanations (SHAP) is provided to offer deep insights into model predictions. Our findings reveal the complementary interplay between evlRNA and image-based characteristics, underscoring the significance of integrating diverse modalities in diagnosing early-stage LUAD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
NPJ precision oncology - 8(2024), 1 vom: 26. Feb., Seite 50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yanwei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41698-024-00551-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368994449 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368994449 | ||
| 003 | DE-627 | ||
| 005 | 20240229235240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41698-024-00551-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM368994449 | ||
| 035 | |a (NLM)38409480 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yanwei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multimodal fusion of liquid biopsy and CT enhances differential diagnosis of early-stage lung adenocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a This research explores the potential of multimodal fusion for the differential diagnosis of early-stage lung adenocarcinoma (LUAD) (tumor sizes < 2 cm). It combines liquid biopsy biomarkers, specifically extracellular vesicle long RNA (evlRNA) and the computed tomography (CT) attributes. The fusion model achieves an impressive area under receiver operating characteristic curve (AUC) of 91.9% for the four-classification of adenocarcinoma, along with a benign-malignant AUC of 94.8% (sensitivity: 89.1%, specificity: 94.3%). These outcomes outperform the diagnostic capabilities of the single-modal models and human experts. A comprehensive SHapley Additive exPlanations (SHAP) is provided to offer deep insights into model predictions. Our findings reveal the complementary interplay between evlRNA and image-based characteristics, underscoring the significance of integrating diverse modalities in diagnosing early-stage LUAD | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Sun, Beibei |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Fangfei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tianxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jiancheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ligang |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Baohui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ precision oncology |d 2017 |g 8(2024), 1 vom: 26. Feb., Seite 50 |w (DE-627)NLM274781727 |x 2397-768X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:26 |g month:02 |g pages:50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41698-024-00551-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 26 |c 02 |h 50 | ||